Tirzepatide
฿4,000.00
- Mechanism: Dual GIP-R / GLP-1R agonist; once-weekly incretin analog with combined receptor co-activation
- Format: Lyophilized powder, 30mg per vial, >99% purity by HPLC
- Included: Vial + Certificate of Analysis (HPLC + mass spectrum)
For research use only. Not for human or veterinary consumption. In-vitro laboratory use only.
Description
Product Specifications
| Peptide | Tirzepatide |
|---|---|
| Also known as | LY3298176 • Mounjaro (brand, not supplied) |
| CAS Number | 2023788-19-2 |
| Molecular Weight | 4,813.5 Da |
| Quantity per vial | 30mg |
| Format | Lyophilized powder (white to off-white) |
| Purity | >99% by HPLC |
| Peptide content | ≥90% net peptide (adjusted for water and counter-ions) |
| Verification method | External HPLC chromatography + mass spectrometry |
| Certificate of Analysis | Provided digitally with every shipment |
| Reconstitution | Sterile water for injection or 0.1% acetic acid |
| Storage — lyophilized | −20°C, sealed vial, away from moisture and light |
| Storage — in solution | −80°C; use within 30 days; avoid freeze-thaw cycles |
| Shelf life | 24 months from manufacture date (lyophilized, correct storage) |
| Intended use | In-vitro laboratory research only. Not for human or veterinary use. |
Research Background
Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIP-R) and the glucagon-like peptide-1 receptor (GLP-1R). It is structurally based on the native GIP sequence with modifications that enable GLP-1R co-agonism. Unlike single-target GLP-1R agonists such as semaglutide, tirzepatide’s dual receptor activity produces additive effects on insulin secretion, gastric emptying, and satiety signaling in preclinical models.
Phase 3 clinical data from the SURPASS trial program (2022) showed mean body weight reductions of up to 22.5% at 72 weeks in adults with type 2 diabetes. The dual incretin mechanism has been the subject of extensive in-vitro research examining the relative contributions of GIP-R and GLP-1R activation to downstream cAMP generation, insulin secretion from pancreatic beta cells, and glucagon suppression. Tirzepatide provides a well-characterized tool compound for comparative incretin receptor pharmacology.
Research Applications
- Dual GIP-R / GLP-1R co-activation studies and receptor-specific downstream signaling separation
- cAMP accumulation dose-response characterization in GIP-R and GLP-1R expressing cell lines
- Pancreatic beta-cell insulin secretion assays under glucose-stimulated and basal conditions
- Glucagon suppression studies in alpha-cell models
- Comparative receptor binding affinity: tirzepatide vs. semaglutide vs. native GIP and GLP-1
- Gastric motility and satiety neuropeptide pathway characterization in enteroendocrine cell models
- GLP-1R + GIP-R internalization and receptor desensitization kinetics studies
Reconstitution Protocol
Allow the vial to equilibrate to room temperature before opening. Reconstitute in sterile water for injection or 0.1% acetic acid at the working concentration required by your assay. Do not vortex; gently swirl or invert the vial until fully dissolved. Filter through a 0.22 μm sterile membrane for cell-based assays where sterility is required. Aliquot into single-use volumes to eliminate freeze-thaw cycling.
Storage and Stability
Store lyophilized vials at −20°C in the original sealed container, protected from moisture and light. Lyophilized material stays stable for up to 24 months from the manufacture date shown on the Certificate of Analysis. Reconstituted peptide solutions should be stored at −80°C and used within 30 days. Avoid repeated freeze-thaw cycles, which degrade the peptide over time.
What’s Included
- 1 × Tirzepatide lyophilized vial — 30mg
- Independent Certificate of Analysis (HPLC chromatogram + mass spectrum + batch data)
- Batch number and expiry date printed on vial label
- Discreet external packaging with no product name or branding on the exterior
Leave a Comment